Search
tebentafusp-tebn (Kimmtrak)
Indications:
- uveal melanoma
Mechanism of action:
- T-cell receptor bispecific immunotherapy
- bispecific gp100 peptide-HLA-directed CD3 T-cell engager
- has high-affinity T-cell receptor binding domain & an anti-CD3 T-cell engaging domain, which redirects T cells to kill gp100-expressing tumor cells
- the T-cell receptor binding domain only recognizes a specific gp100-derived peptide presented on HLA-A*02:01, thus tebentafusp can only be used to treat patients with this HLA type.
General
biological response modifier; immune factor; immunomodulator; biomodulator
antineoplastic agent (chemotherapeutic agent)
References
- Chustecka Z
Novel Drug, First Tx Approved for Rare Uveal Melanoma.
Medscape. Jan 27, 2022
https://www.medscape.com/viewarticle/967360
- Nathan P, Hassel JC, Rutkowski P et al
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med 2021; 385:1196-1206
PMID: 34551229 Free article
https://www.nejm.org/doi/full/10.1056/NEJMoa2103485